Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CRX100 |
| Synonyms | |
| Therapy Description |
CRX100 consists of autologous cytokine-induced killer cells harboring the oncolytic vaccinia virus DD-CDSR, which may deliver oncolytic viruses to tumor cells and induce anti-tumor immune response (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CRX100 | CRX-100|CRX 100 | CRX100 consists of autologous cytokine-induced killer cells harboring the oncolytic vaccinia virus DD-CDSR, which may deliver oncolytic viruses to tumor cells and induce anti-tumor immune response (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04282044 | Phase I | CRX100 | Study of CRX100 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |